Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (301)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07443176 | FCI-Glioblastoma Study | not yet recruiting | — | 18 | University of AberdeenOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06625047 | Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy | completed | Phase 4 | 30 | Mayo ClinicOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07297212 |
| A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma |
| recruiting |
| Phase 2 |
| 75 |
| BioNTech SEINDUSTRY |
| 1 |
| Apr 29, 2026 |
| clinicaltrials |
| NCT04922723 | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma(PRIDE) | active not recruiting | Phase 1 / Phase 2 | 16 | West Virginia UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06039709 | Sonodynamic Therapy in Patients With Recurrent GBM(GBM 001) | recruiting | Phase 1 | 11 | Shayan Moosa, MDOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07553520 | Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients | withdrawn | N/A | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552233 | NK Cell Therapy for Malignant Solid Brain Tumors | recruiting | N/A | 27 | Peking University Third HospitalOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07552467 | Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors | recruiting | — | 26 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05513859 | Investigational Imaging Technique During Brain Surgery | suspended | N/A | 24 | Emory UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05565521 | UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly(UNITED2) | active not recruiting | Phase 2 | 55 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07551336 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02631655 | POSitron Emission Imaging Using 18F-FDOPA in Neurooncology(POSEIDON) | completed | N/A | 110 | Centre Antoine LacassagneOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03383978 | Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma(CAR2BRAIN) | recruiting | Phase 1 | 42 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03961971 | Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM | active not recruiting | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors | terminated | — | 57 | Pediatric Brain Tumor ConsortiumNETWORK | 2 | Apr 23, 2026 | clinicaltrials |
| NCT07546669 | Efficacy of Zoster Vaccination in Glioblastoma Patients(STARGATE) | not yet recruiting | Phase 4 | 230 | University Hospital, EssenOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT04396860 | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | completed | Phase 2 / Phase 3 | 159 | National Cancer Institute (NCI)NIH | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05366179 | Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc | recruiting | Phase 1 | 36 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05917145 | ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma | recruiting | Phase 1 | 94 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06336291 | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence(GLIOSTELLA) | active not recruiting | Phase 2 | 90 | Philogen S.p.A.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07538128 | Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | recruiting | Early Phase 1 | 10 | Huashan HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02287428 | Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM | active not recruiting | Phase 1 | 56 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04656535 | AB154 Combined With AB122 for Recurrent Glioblastoma | active not recruiting | Early Phase 1 | 46 | Yale UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04817254 | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06466031 | Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO](TYR-GLIO) | recruiting | N/A | 189 | Copernicus Memorial HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04998864 | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients | completed | — | 3 | InSightecINDUSTRY | 2 | Apr 16, 2026 | clinicaltrials |
| NCT03451799 | Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma | completed | Phase 1 | 21 | Jethro HuOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04670016 | HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers | completed | — | 20 | University of CalgaryOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04762069 | A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme | active not recruiting | Phase 2 | 252 | CNS Pharmaceuticals, Inc.INDUSTRY | 5 | Apr 15, 2026 | clinicaltrials |
| NCT07532031 | APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas(APT-HGG) | not yet recruiting | — | 20 | IRCCS Ospedale San RaffaeleOTHER | 0 | Apr 15, 2026 | clinicaltrials |
| NCT01507506 | Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma(SPECTRO GLIO) | terminated | Phase 3 | 180 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01872221 | Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study(STEMRI) | completed | N/A | 21 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02866747 | A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma(STERIMGLI) | completed | Phase 1 / Phase 2 | 108 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06512311 | Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening(ATTRACT) | recruiting | N/A | 240 | Medical University of ViennaOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07185880 | A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients(STAR-GBM) | recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02800486 | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | recruiting | Phase 2 | 37 | Northwell HealthOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04528680 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma(SC9/ABX) | active not recruiting | Phase 1 / Phase 2 | 57 | Northwestern UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04988750 | Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients | completed | N/A | 7 | NaviFUS CorporationINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05168423 | CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM | active not recruiting | Phase 1 | 67 | University of PennsylvaniaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06419946 | Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma | recruiting | Phase 3 | 200 | Vastra Gotaland RegionOTHER_GOV | 4 | Apr 13, 2026 | clinicaltrials |
| NCT04446416 | Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients | completed | N/A | 6 | NaviFUS CorporationINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07134842 | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.(WinGlio-ipi) | recruiting | Phase 1 | 16 | University College, LondonOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07301268 | GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma | recruiting | Phase 2 | 36 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07488754 | Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) | recruiting | N/A | 35 | Medical University of WarsawOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511725 | Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma(PRISM) | recruiting | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07497373 | A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma(JL15003) | completed | Phase 1 | 17 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05789394 | Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2026source: clinicaltrials